- JP-listed companies
- Balance sheet
【JP:4597】Balance sheet
Market cap
¥7B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Cash and cash equivalents | - | 2,077 | 1,035 | 3,364 | 4,012 | 4,116 | 2,964 | 714 | 803 | 728 | 886 | 1,387 |
| Total cash & short-term investments | - | 2,077 | 1,035 | 3,364 | 4,012 | 4,116 | 2,964 | 714 | 803 | 728 | 886 | 1,387 |
| Accounts receivable, net | - | - | - | - | 193 | 10 | 173 | 126 | 572 | 67 | 232 | 374 |
| Inventories | - | - | - | - | 122 | 3 | 4 | - | 14 | 122 | 128 | 112 |
| Total current assets | - | 2,104 | 1,126 | 3,517 | 4,482 | 4,302 | 3,269 | 894 | 1,435 | 976 | 1,266 | 1,890 |
| Property, plant and equipment, net | - | 2 | 1 | 1 | 40 | 46 | 43 | 36 | 26 | 21 | 19 | 16 |
| Marketable securities, non-current | - | - | - | - | - | - | - | - | - | - | - | 141 |
| Total non-current assets | - | 36 | 36 | 72 | 106 | 3,644 | 2,506 | 2,249 | 1,698 | 1,252 | 96 | 254 |
| Total assets | - | 2,140 | 1,162 | 3,589 | 7,728 | 7,946 | 5,775 | 3,144 | 3,134 | 2,229 | 1,362 | 2,145 |
| Accounts payable | - | - | - | - | 580 | 800 | 987 | 386 | 332 | 213 | 121 | 229 |
| Total current liabilities | - | 146 | 200 | 374 | 566 | 925 | 2,079 | 489 | 407 | 293 | 193 | 312 |
| Total non-current liabilities | - | 2,939 | 1 | 1 | 52 | 103 | 43 | 67 | 64 | 61 | 12 | 80 |
| Total liabilities | - | 3,085 | 202 | 375 | 641 | 1,029 | 2,123 | 556 | 472 | 354 | 206 | 393 |
| Retained earnings | - | -6,088 | -7,146 | -8,712 | -11,244 | 1,400 | -2,726 | -5,204 | -223 | -1,336 | -3,277 | -521 |
| Stockholders' equity | -964 | -945 | 960 | 3,214 | 3,970 | 6,917 | 3,652 | 2,587 | 2,662 | 1,875 | 1,156 | 1,620 |
| Working capital | - | - | - | - |